REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Baum, Alina, Ajithdoss, Dharani, Copin, Richard, Zhou, Anbo, Lanza, Kathryn, Negron, Nicole, Ni, Min, Wei, Yi +28 more·2020·Science
DOI 10.1126/science.abe2402

Cited by (524)

Items 201–300 of 524

  1. Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines
    Xiaoqing Guan, Yang Yang, Lanying Du · 2023 · Expert Review of Vaccines
  2. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency
    K. Honjo, Ronnie M. Russell, Ran Li, Wei-Min Liu, R. Stoltz, E. Tabengwa, Yu-Tao Hua, L. Prichard, A. Kornbrust, S. Sterrett et al. · 2020 · Cell Reports Medicine
  3. SARS-CoV-2 cell entry and targeted antiviral development
    Zi-Nuo Chen, R. Du, Jazmin M. Galván Achi, Li-Jun Rong, Q. Cui · 2021 · Acta Pharmaceutica Sinica B
  4. SARS-CoV-2: Origin, Evolution, and Targeting Inhibition
    Shuo Ning, Beiming Yu, Yanfeng Wang, Feng Wang · 2021 · Frontiers in Cellular and Infection Microbiology
  5. Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing
    Irene Maeve Rea, H. Denis Alexander · 2021 · Ageing Research Reviews
  6. Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease
    Bennett J. Davenport, Alexis Catala, S. Weston, Robert M. Johnson, J. Ardanuy, H. Hammond, C. Dillen, M. Frieman, C. Catalano, T. Morrison · 2021 · npj Vaccines
  7. Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo
    James Anthony Torchia, Alexander H. Tavares, Laura Stentoft Carstensen, D. W. Chen, Jessie Huang, Tianshu Xiao, Sonia Mukherjee, Patrick M. Reeves, Hua Tu, Ann E. Sluder et al. · 2022 · Science Advances
  8. Overview of Nonhuman Primate Models of SARS-CoV-2.
    A. Trichel · 2021 · Comparative medicine
  9. Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform
    Kaushik Chakravarty, Victor G. Antontsev, Maksim Khotimchenko, Nilesh Gupta, Aditya Jagarapu, Yogesh Bundey, Hypatia Hou, Neha V. Maharao, Jyotika Varshney · 2021 · Molecules
  10. Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies
    F. Lempp, Leah B. Soriaga, Martin Montiel-Ruiz, F. Benigni, Julia Noack, Young-Jun Park, S. Bianchi, A. Walls, J. Bowen, Jia-Yi Zhou et al. · 2021 · bioRxiv
  11. Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines
    Ahmed Yaqinuddin, Areez Shafqat, Junaid Kashir, Khaled Manae AlKattan · 2021 · Vaccines
  12. Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time
    Timothy F. Czajka, David J. Vance, Nicholas John Mantis · 2020 · Trends in Microbiology
  13. Potential COVID‐19 Therapeutic Agents and Vaccines: An Evidence‐Based Review
    Elnaz Khani, Sajad Khiali, Taher Entezari‐Maleki · 2021 · The Journal of Clinical Pharmacology
  14. COVID-19 in Children
    Ramón Armando Ruiz Galindo, Heather Chow, Chokechai Rongkavilit · 2021 · Pediatric Clinics of North America
  15. Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
    Zhaochun Chen, Peng Zhang, Yumiko Matsuoka, Yaroslav Tsybovsky, Kamille A. West, Celia P. Santos, Lisa F. Boyd, Hanh Nguyen, Anna Pomerenke, Tyler Stephens et al. · 2022 · Cell Reports
  16. Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge
    M. Winkler, T. Skirecki, F. Brunkhorst, S. Cajander, J. Cavaillon, R. Ferrer, S. Flohé, A. García-Salido, E. Giamarellos-Bourboulis, M. Girardis et al. · 2021 · EBioMedicine
  17. p‐cymene impairs SARS‐CoV‐2 and Influenza A (H1N1) viral replication: In silico predicted interaction with SARS‐CoV‐2 nucleocapsid protein and H1N1 nucleoprotein
    Athanasios A. Panagiotopoulos, Melpomeni Tseliou, Ioannis Karakasiliοtis, Danai Maria Kotzampasi, Vangelis Daskalakis, Nikolaos Kesesidis, George Notas, Christos D Lionis, Marilena Kampa, Stergios Pirintsos et al. · 2021 · Pharmacology Research & Perspectives
  18. Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections
    Balamurugan Shanmugaraj, Konlavat Siriwattananon, Ashwini Malla, Waranyoo Phoolcharoen · 2021 · Pathogens
  19. SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications
    Lunzhi Yuan, Qiyi Tang, Huachen Zhu, Yi Guan, Tong Cheng, Ningshao Xia · 2021 · Emerging Microbes & Infections
  20. The Relevance of Monoclonal Antibodies in the Treatment of COVID-19
    Anabel Torrente-López, Jesús Hermosilla, Natalia Navas, Luis Cuadros-Rodrı́guez, José Cabeza Barrera, Antonio Salmerón‐García · 2021 · Vaccines
  21. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study
    Shelly Karuna, Shuying Sue Li, Shannon Grant, Stephen R. Walsh, Ian Frank, Martín Casapía, Meg Trahey, Ollivier Hyrien, Leigh H. Fisher, Maurine D. Miner et al. · 2021 · PLoS Medicine
  22. Plant Molecular Pharming and Plant-Derived Compounds towards Generation of Vaccines and Therapeutics against Coronaviruses
    Srividhya Venkataraman · 2022 · Vaccines
  23. Development of SARS-CoV-2 entry antivirals
    Meiyue Dong, Jazmin Galván Achi, Ruikun Du, Lijun Rong, Qinghua Cui · 2024 · Cell Insight
  24. COVID-19 clinical presentation, management, and epidemiology: a concise compendium
    David P. Maison, Hawi Tasissa, Amelia N. Deitchman, Michael J. Peluso, Youping Deng, F. DeWolfe Miller, Timothy J. Henrich, Mariana Gerschenson · 2025 · Frontiers in Public Health
  25. An update to “novel therapeutic approaches for treatment of COVID-19”
    Nikoo Hossein‐Khannazer, Bahare Shokoohian, Anastasia I. Shpichka, Hamid Asadzadeh Aghdaei, Peter S. Timashev, Massoud Vosough · 2021 · Journal of Molecular Medicine
  26. Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques
    K. V. van Rompay, K. Olstad, R. Sammak, Joseph C. Dutra, Jennifer K. Watanabe, J. Usachenko, Ramya Immareddy, A. Verma, Yashavanth Shaan Lakshmanappa, B. Schmidt et al. · 2021 · PLoS Pathogens
  27. Hamsters as a Model of Severe Acute Respiratory Syndrome Coronavirus-2
    Alicia M. Braxton, Patrick S. Creisher, Camilo A. Ruiz-Bedoya, Katie R Mulka, Santosh Dhakal, Alvaro A. Ordoñez, Sarah E. Beck, Sanjay Kumar Jain, Jason Villano · 2021 · Comparative Medicine
  28. Effect of SARS-CoV-2 spike mutations on animal ACE2 usage and in vitro neutralization sensitivity
    Weitong Yao, Danting Ma, Haimin Wang, Xiaojuan Tang, Chengzhi Du, Hong Pan, Chao Li, Hua Lin, Michael Farzan, Jincun Zhao et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  29. Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection
    Arnaud John Kombe Kombe, Ayesha Zahid, Ahmed Mohammed, Ronghua Shi, Tengchuan Jin · 2021 · Frontiers in Molecular Biosciences
  30. Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters
    Rakesh Kulkarni, Wen-Ching Chen, Ying Lee, Chi‐Fei Kao, Shiu-Lok Hu, Hsiu‐Hua Ma, Jia‐Tsrong Jan, Chun‐Che Liao, Jian‐Jong Liang, Hui‐Ying Ko et al. · 2021 · PLoS ONE
  31. Global trends in COVID-19
    Chuan‐Min Zhou, Xiang‐Rong Qin, Lina Yan, Yuan Jiang, Xue‐jie Yu · 2022 · Infectious Medicine
  32. The Wnt/β-catenin pathway is important for replication of SARS-CoV-2 and other pathogenic RNA viruses
    Zaikun Xu, Mohamed Elaish, Cheung Pang Wong, Bardes B. Hassan, Joaquín López-Orozco, Alberto Felix-Lopez, Natacha S. Ogando, Les P. Nagata, Lara K. Mahal, Anil Kumar et al. · 2024 · npj Viruses
  33. The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development
    Zhen Zhang, Li Zhou, Qianyun Liu, Yucheng Zheng, Xue Tan, Zhixiang Huang, Ming Sen Guo, Xin Wang, Xianying Chen, Simeng Liang et al. · 2024 · Emerging Microbes & Infections
  34. A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques
    Ronald R. Cobb, Joseph P. Nkolola, P. Gilchuk, A. Chandrashekar, Jing-You Yu, R. House, C. Earnhart, N. Dorsey, S. Hopkins, Doris M. Snow et al. · 2022 · i Medicina
  35. Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants
    Anna R. Mäkelä, Hasan Uğurlu, Liina Hannula, Ravi Kant, Petja Salminen, Riku Fagerlund, Sanna Mäki, Anu Haveri, Tomas M. Strandin, Lauri Kareinen et al. · 2023 · Nature Communications
  36. Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection
    Daria V. Voronina, Dmitry V. Shcheblyakov, Irina A. Favorskaya, Ilias B. Esmagambetov, Alina Sh. Dzharullaeva, Тухватулин Амир Ильдарович, Olga V. Zubkova, Olga D. Popova, Vladislav Y. Kan, Банделюк Алина Сергеевна et al. · 2022 · Viruses
  37. A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection
    L. Adams, Laura A. VanBlargan, Zhuo-Ming Liu, P. Gilchuk, Hai-Yan Zhao, Rita E. Chen, S. Raju, Zhen-Lu Chong, Bradley M. Whitener, S. Shrihari et al. · 2023 · Cell Reports Medicine
  38. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
    Caroline Hirsch, Sarah J Valk, V. Piechotta, K. Chai, L. Estcourt, I. Monsef, S. Salomon, Eve Tomlinson, Maria Popp, E. Wood et al. · 2021 · Cochrane Database of Systematic Reviews
  39. Liquid Chromatography-Multiple Reaction Monitoring-Mass Spectrometry Assay for Quantitative Measurement of Therapeutic Antibody Cocktail REGEN-COV Concentrations in COVID-19 Patient Serum
    Xuefei Zhong, Shruti Nayak, Lili Guo, Shivkumar Raidas, Yunlong Zhao, Rachel Weiss, Matthew D. Andisik, Chinnasamy Elango, Giane Sumner, Susan C. Irvin et al. · 2021 · Analytical Chemistry
  40. SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants
    Almu'atasim Khamees, J. Bani-Issa, Mazhar Salim Al Zoubi, Taqwa Qasem, M. I. AbuAlarjah, Sura Ahmad Alawadin, K. Al-Shami, F. E. Hussein, Emad Ibraheim Hussein, Ibrahim H. Bashayreh et al. · 2022 · Pathogens
  41. Antibody-Based Immunotherapeutic Strategies for COVID-19
    Jamal Hussen, Mahmoud K Kandeel, Maged Gomaa Hemida, Abdullah I. A. Al-Mubarak · 2020 · Pathogens
  42. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
    Wen Su, Sin Fun Sia, Aaron J. Schmitz, Traci L. Bricker, Tyler N. Starr, Allison J. Greaney, Jackson S. Turner, Bassem M. Mohammed, Zhuoming Liu, Ka Tim Choy et al. · 2021 · mBio
  43. Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22)
    Xilin Wu, Yaxin Wang, Lin Cheng, Fengfeng Ni, Linjing Zhu, Sen Ma, Bilian Huang, Mengmeng Ji, Huimin Hu, Yuncheng Li et al. · 2022 · Frontiers in Immunology
  44. Development of broadly neutralizing antibodies targeting the cytomegalovirus subdominant antigen gH
    Andrea Jean Parsons, Sabrina I. Ophir, J. Andrew Duty, Thomas Kraus, Kathryn R. Stein, Thomas M. Moran, Domenico Tortorella · 2022 · Communications Biology
  45. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants
    Efi Makdasi, Anat Zvi, Ron Alcalay, Tal Noy-Porat, Eldar Peretz, Adva Mechaly, Yinon Levy, Eyal Epstein, Theodor Chitlaru, Ariel Tennenhouse et al. · 2021 · Cell Reports
  46. XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants
    B. Vanhove, S. Marot, Ray T. Y. So, B. Gaborit, G. Evanno, I. Malet, Guillaume Lafrogne, Edwige Mevel, C. Ciron, Pierre-Joseph Royer et al. · 2021 · Frontiers in Immunology
  47. Cocktail of REGN Antibodies Binds More Strongly to SARS-CoV-2 Than Its Components, but the Omicron Variant Reduces Its Neutralizing Ability
    Hung Van Nguyen, Pham Dang Lan, Daniel Allen Nissley, Edward P. O’Brien, Mai Suan Li · 2022 · The Journal of Physical Chemistry B
  48. Decay of Fc-dependent antibody functions after mild to moderate COVID-19
    Lee, Wen Shi, Selva, Kevin John, Davis, Samantha K., Wines, Bruce D., Reynaldi, Arnold, Esterbauer, Robyn, Kelly, Hannah G., Haycroft, Ebene R., Tan, Hyon-Xhi, Juno, Jennifer A. et al. · 2020
  49. Monoclonal antibodies for treating COVID-19
    Andrea M. Pallotta, ChungYun Kim, Steven Mark Gordon, Alice Kim · 2021 · Cleveland Clinic Journal of Medicine
  50. The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines
    Kensaku Murano, Youjia Guo, Haruhiko Siomi · 2021 · Biochemical Society Transactions
  51. SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity
    Shi Yu, Huina Hu, Qiangyun Ai, Rong Bai, Kaixiong Ma, Minmin Zhou, Shaobo Wang · 2023 · Viruses
  52. Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants
    Mellissa C. Alcantara, Yusuke Higuchi, Yuhei Kirita, Satoaki Matoba, Atsushi Hoshino · 2023 · Vaccines
  53. Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein
    Yuting Hong, Huilin Guo, Min Wei, Yali Zhang, Mujin Fang, Tong Cheng, Zhiyong Li, Shengxiang Ge, Xiangyang Yao, Quan Yuan et al. · 2022 · Journal of Virological Methods
  54. COVID-19 and Gut Injury
    Sj Shen, Muxue Gong, Gang Wang, Kamal Dua, Jincheng Xu, Xiaoyue Xu, Gang Liu · 2022 · Nutrients
  55. REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 Results
    Thomas D. Norton, Shazia Ali, Sumathi Sivapalasingam, Haitao Gao, Rafia Bhore, Andrea T. Hooper, Jennifer D. Hamilton, Bret J. Musser, Diana Rofail, Joseph Im et al. · 2021 · medRxiv
  56. SARS-CoV2 infects pancreatic beta cells in vivo and induces cellular and subcellular disruptions that reflect beta cell dysfunction
    Katelyn Millette, Janielle Cuala, Pei-Yu Wang, C. Marks, Veronica Woo, Maya Hayun, Harsimar Kang, Martin Martin, S. Dhawan, Lily Chao et al. · 2021 · Research Square
  57. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy
    Lorenzo Iovino, Laurel A. Thur, Sacha Gnjatic, Aude G. Chapuis, Filippo Milano, Joshua Aiden Hill · 2021 · Journal for ImmunoTherapy of Cancer
  58. Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation
    A. Verma, Chase Hawes, Y. S. Lakshmanappa, Jamin W. Roh, B. Schmidt, Joseph C. Dutra, William Louie, Hong-Wei Liu, Zhong-Min Ma, Jennifer K. Watanabe et al. · 2021 · Cell Reports
  59. Host Cell Membrane Capture by the SARS-CoV-2 Spike Protein Fusion Intermediate
    Rui Su, Jin Zeng, Tara C. Marcink, Matteo Porotto, Anne Moscona, Ben O’Shaughnessy · 2023 · ACS Central Science
  60. Corilagin and 1,3,6-Tri- O -galloy-β- d -glucose: potential inhibitors of SARS-CoV-2 variants
    Vincent Binette, Sébastien Côté, Mohamed Haddad, Phuong Trang Nguyen, Sébastien Bélanger, Steve Bourgault, Charles Ramassamy, Roger Gaudreault, Normand Mousseau · 2021 · Physical Chemistry Chemical Physics
  61. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization
    Maggie Gu, J. Torres, Yi-Jia Li, Alex Van Ry, Jack Greenhouse, Shannon E. Wallace, Chi-I Chiang, Laurent Pessaint, A. Jackson, Maciel Porto et al. · 2021 · Emerging Microbes and Infections
  62. SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters 1
    Biao Zhou, Runhong Zhou, Jasper Fuk‐Woo Chan, Jianwei Zeng, Qi Zhang, Shuofeng Yuan, Li Liu, Rémy Robinot, Sisi Shan, Na Liu et al. · 2023 · Emerging Microbes & Infections
  63. Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques
    T. Nomura, Hiroyuki Yamamoto, M. Nishizawa, T. Hau, S. Harada, Hiroshi Ishii, Sayuri Seki, Midori Nakamura-Hoshi, Midori Okazaki, Sachie Daigen et al. · 2021 · bioRxiv
  64. Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants
    Tatsuhiko Ozawa, Hideki Tani, Yuki Anraku, Shunsuke Kita, Emiko Igarashi, Yumiko Saga, Noriko Inasaki, Hitoshi Kawasuji, Hiroshi Yamada, Soichiro Sasaki et al. · 2022 · mAbs
  65. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening
    Xuehua Yang, Huarui Duan, Xiuying Liu, Xinhui Zhang, Shengnan Pan, Fangyuan Zhang, Peixiang Gao, Бо Лю, Jian Yang, Xiaojing Chi et al. · 2023 · Journal of Virology
  66. Deciphering Fc-effector functions against SARS-CoV-2
    Guillaume Beaudoin-Bussières, Andrés Finzi · 2024 · Trends in Microbiology
  67. Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1
    Zhou Tong, Jianyu Tong, Wenwen Lei, Yufeng Xie, Yingzi Cui, Guowen Jia, Shihua Li, Zezhong Zhang, Zhimin Cheng, Xiao Xing et al. · 2024 · Cell Reports
  68. A cocktail of antibodies for COVID-19 therapy
    Dean B. Matthews · 2020 · Nature reviews. Immunology
  69. Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations
    Abdul Aleem, Amy K. Slenker · 2021 · Europe PMC (PubMed Central)
  70. Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies
    Carolina Corrêa Giron, Aatto Laaksonen, Fernando Luís Barroso da Silva · 2022 · Journal of Biomolecular Structure and Dynamics
  71. Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail
    Qingbing Zheng, Rui Zhu, Zhichao Yin, Longfa Xu, Hui Sun, Hai Jing Yu, Yuanyuan Wu, Yichao Jiang, Qiongzi Huang, Yang Huang et al. · 2022 · Cell Host & Microbe
  72. Targeting SARS‐CoV ‐2 infection through CAR‐T ‐like bispecific T cell engagers incorporating ACE2
    Mikail Dogan, Lina Kozhaya, Lindsey Placek, Fatih Karabacak, Mesut Yiğit, Derya Unutmaz · 2022 · Clinical & Translational Immunology
  73. The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
    Aline Almeida-Oliveira, Diana Praia Borges Freire, Ana Rodrigues de Andrade, Amanda de Miranda Marques, Luciana da Silva Madeira, Jose Procopio Moreno Senna, Ivna Alana Freitas Brasileiro da Silveira, Beatriz de Castro Fialho · 2023 · Journal of Pharmaceutical Innovation
  74. Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient
    Lena Jaki, Sebastian Weigang, Lisa Kern, Stefanie Kramme, Antoni G. Wrobel, Andrea Busse Grawitz, Philipp Nawrath, Stephen R. Martin, Theo Dähne, Julius Beer et al. · 2023 · Nature Communications
  75. Neutralizing and enhancing antibodies against SARS-CoV-2
    Yafei Liu, Hisashi Arase · 2022 · Inflammation and Regeneration
  76. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants
    S. Changrob, P. Halfmann, Hejun Liu, J. Torres, J. McGrath, G. Ozorowski, Lei Li, G. Wilbanks, M. Kuroda, Tadashi Maemura et al. · 2023 · Journal of Clinical Investigation
  77. High-Throughput Approaches of Diagnosis and Therapies for COVID-19: Antibody Panels, Proteomics and Metabolomics
    Rwik Sen · 2020 · Future Drug Discovery
  78. COVID-19 Therapeutics and Vaccines: A Race to Save Lives
    Ilona Bebenek, Roy M. Bannister, John Harvey Dubinion, Marie Fortin, Matt Liu, Arianne L. Motter, Cynthia M. Rohde, Claudia Wrzesinski · 2021 · Toxicological Sciences
  79. A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain
    Xinyue Chang, A. Zeltins, M. Mohsen, Zahra Gharailoo, L. Zha, Xue-Lan Liu, S. Walton, M. Vogel, M. Bachmann · 2021 · Vaccines
  80. ACE2 : S1 RBD Interaction-Targeted Peptides and Small Molecules as Potential COVID-19 Therapeutics
    L. Chitsike, J. Krstenansky, P. Duerksen-Hughes · 2021 · Advances in pharmacological and pharmaceutical sciences
  81. A monoclonal antibody neutralizes pesudorabies virus by blocking gD binding to the receptor nectin-1
    Teng Zhang, Yunchao Liu, Yumei Chen, Jucai Wang, Hua Feng, Qiang Wei, Shuangshuang Zhao, Suzhen Yang, Dongmin Liu, Gaiping Zhang · 2021 · International Journal of Biological Macromolecules
  82. Insights Into the Changing Landscape of Coronavirus Disease 2019
    Ruby A. Escobedo, Deepak Kaushal, Dhiraj Kumar Singh · 2022 · Frontiers in Cellular and Infection Microbiology
  83. SARS-CoV-2 spike therapeutic antibodies in the age of variants
    Alina Baum, Christos A. Kyratsous · 2021 · The Journal of Experimental Medicine
  84. Epitope mapping of neutralising anti‐SARS‐CoV‐2 monoclonal antibodies: Implications for immunotherapy and vaccine design
    Somayeh Ghotloo, Faezeh Maghsood, Forough Golsaz‐Shirazi, Mohammad Mehdi Amiri, Christiane Moog, Fazel Shokri · 2022 · Reviews in Medical Virology
  85. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
    Simone Pecetta, Sven Kratochvil, Yu Kato, Kumaran Vadivelu, Rino Rappuoli · 2022 · Pharmacological Reviews
  86. Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model
    Maya Imbrechts, Wim Maes, Louanne Ampofo, Nathalie Van den Berghe, Bas Calcoen, Dominique Van Looveren, Winnie Kerstens, Madina Rasulova, Thomas Vercruysse, Sam Noppen et al. · 2022 · iScience
  87. SARS-CoV-2 spike host cell surface exposure promoted by a COPI sorting inhibitor
    Yiqun Li, Mingrui Yang, Yanan Nan, Jiaming Wang, Sanjiao Wang, Dongxiao Cui, Jiajian Guo, Pengfei He, Wenxin Dai, Shuqi Zhou et al. · 2023 · Acta Pharmaceutica Sinica B
  88. Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy
    Dongyan Zhou, Run-Hong Zhou, Zhi-Wei Chen · 2021 · Immunotherapy Advances
  89. IMM-BCP-01, a patient-derived anti–SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2
    Pavel A. Nikitin, Jillian M. DiMuzio, John P. Dowling, Nirja B. Patel, Jamie L. Bingaman, Baron C. Heimbach, Noeleya Henriquez, Chris Nicolescu, Antonio M Polley, Eden L. Sikorski et al. · 2022 · Science Immunology
  90. Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model
    Takuya Tada, Belinda M. Dcosta, Hao Zhou, Nathaniel Roy Landau · 2023 · iScience
  91. A Polysaccharide-RBD-Fc-Conjugated COVID-19 Vaccine, SCTV01A, Showed High Immunogenicity and Low Toxicity in Animal Models
    Chunyun Sun, Desheng Kong, Erhong Guo, Jun Fang Zhao, Jilei Jia, Rui Wang, Juan Ma, Meng Chen, Jianbo Lu, Chulin Yu et al. · 2023 · Vaccines
  92. Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2
    Meghan M. Verstraete, Florian Heinkel, Janessa Li, Siran Cao, Anh Tran, Elizabeth C. Halverson, Robert W. Gene, Elizabeth Stangle, Begonia Silva‐Moreno, Sifa Arrafi et al. · 2023 · mAbs
  93. An Overview of the Conventional and Novel Methods Employed for SARS-CoV-2 Neutralizing Antibody Measurement
    Vinícius Pinto Costa Rocha, Helenita Costa Quadros, Antônio Márcio Santana Fernandes, Luana Pereira Gonçalves, Roberto José da Silva Badaró, Milena Botelho Pereira Soares, Bruna Aparecida Souza Machado · 2023 · Viruses
  94. Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2
    Ismail Celil Haskologlu, Emine Erdağ, Serkan Sayıner, Nurettin Abacıoğlu, Ahmet Özer Şehirli · 2022 · Molecular Biology Reports
  95. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation
    K. V. van Rompay, K. Olstad, R. Sammak, Joseph C. Dutra, Jennifer K. Watanabe, J. Usachenko, Ramya Immareddy, Jamin W. Roh, A. Verma, Yashavanth Shaan Lakshmanappa et al. · 2022 · PLoS Pathogens
  96. Nonhuman primate models for SARS-CoV-2 research: Infrastructure needs for pandemic preparedness
    S. Hild, Michael C. Chang, Stephanie J. Murphy, F. Grieder · 2021 · Lab animal
  97. Bamlanivimab Use in a Military Treatment Facility
    Eric Karr, Theodore Chung, Kathryn M Burtson, Ronald Markert, Devin Kelly · 2021 · Military Medicine
  98. A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients
    Deanna J. Buehrle, Robert R. Sutton, Erin L. McCann, AARON E. LUCAS · 2021 · Viruses
  99. Modifications of lipid pathways restrict SARS-CoV-2 propagation in human induced pluripotent stem cell-derived 3D airway organoids
    Ping‐Hsing Tsai, Jun‐Ren Sun, Yueh Chien, Man Sheung Chan, Winnie Khor, Hsin‐Chou Yang, Chih-Heng Huang, Chia‐Ni Hsiung, Teh-Yang Hwa, Yi‐Ying Lin et al. · 2023 · Journal of Advanced Research
  100. Emergence of SARS and COVID-19 and preparedness for the next emerging disease X
    Ben Hu, Hua Guo, Haorui Si, Zhengli Shi · 2024 · Frontiers in Medicine